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Objective: The role of non-invasive positive pressure ventilation (NPPV) in stable
COPD with chronic ventilatory failure remains controversial. The impact of long-
term home nocturnal NPPV treatment on deflation has not yet been evaluated in
detail.
Methods: Retrospective explorative study of 46 patients with stable COPD under-
going NPPV treatment. Effects of NPPV on bodyplethysmographic parameters, blood
gas tensions and inspiratory muscle function after 6.2 (71.7) and 12.7 (72.1)
months of treatment. Further, evaluation of 1-year survival, compliance and
ventilation parameters.
Results: One-year survival was 89.1%. The effectiveness of ventilation was proven
by a significant reduction in nocturnal and daytime PaCO2. We observed a decrease
in the ratio of residual volume (RV) to total lung capacity (TLC) on the average of
5.279.8% (or 15.2729.7% pred.; Po0:01) at six and 3.979.0% (or 12.9718.6%
pred.; Po0:001) at 12 months. As a consequence, we found significant improvements
in inspiratory capacity (IC), vital capacity (VC) and forced expiratory volume in one
second (FEV1). For patients with the most severe hyperinflation (RV/TLC475%), we
found a significant positive correlation between inspiratory positive airway pressure
(IPAP) and reductions in PaCO2 (r ¼ 0:56; Po0:05) and RV/TLC (r ¼ 0:50; Po0:05).Elsevier Ltd. All rights reserved.
MI, body-ass index; CPAP, continuous positive airway pressure; COPD, chronic obstructive
tein; EPAP, expiratory positive airway pressure; EELV, end-expiratory lung volume; FEV1, forced
haemoglobin; HRQL, health-related quality of life; IC, inspiratory capacity; IPAP, inspiratory
rm oxygen therapy; NPPV, non-invasive positive pressure ventilation; P0.1, mouth occlusion
rbon dioxide tension; PaO2, arterial oxygen tension; PEEPi, intrinsic positive end-expiratory
ressure; RV/TLC, ratio residual volume/total lung capacity; SaO2, arterial oxygen saturation;
tal lung capacity; VC, vital capacity
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Reduction of hyperinflation in stable COPD 977Conclusions: In severe hypercapnic stable COPD long-term nocturnal NPPV can
reduce hyperinflation with sustained improved daytime blood gas parameters.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Non-invasive positive pressure ventilation (NPPV)
has attained an important role in the treatment of
COPD with acute respiratory failure by avoiding
intubation and prolonging survival.1–4 Despite the
lack of prospective controlled trials, NPPV is also an
accepted treatment option for chronic ventilatory
failure in patients with neuromuscular and chest
wall diseases,5–9 although controversy remains
regarding the effectiveness of long-term home
ventilation in patients with hypercapnic but stable
COPD.10 Numerous studies have described positive
effects on blood gas parameters, sleep quality and
hospital admission as well as on functional status
and health-related quality of life.11–18 In contrast,
no changes or only marginal improvements in these
parameters were reported in some controlled
investigations, mostly on small samples of COPD
patients.19–22 However, it was noted that these
results were possibly due to patient selection,
ineffective ventilation, poor compliance or too
short of an application time.23–25 Although there is
growing evidence that at least subgroups of COPD
patients profit from NPPV,26,27 the mechanisms
responsible for the beneficial effects, especially
improving blood gas parameters, are not comple-
tely understood and have yet to be defined. More
recently, in a prospective controlled trial, it could
be shown that the short-term use of NPPV during
the day improves blood gas tensions in relation to a
decrease in lung hyperinflation, while no relief in
inspiratory muscle fatigue could be observed.28 To
evaluate the impact on lung deflation of patients
receiving long-term home ventilation, we per-
formed a retrospective analysis of different lung
function parameters including inspiratory capacity
and respiratory muscle function in a collective of
severe symptomatic COPD patients in a stable
status of their disease.Materials and methods
Patient selection
All COPD patients discharged with NPPV from the
respiratory clinic in Donaustauf, University of
Regensburg, Germany from 1995 to October 2003
were retrospectively collected in a computerizeddatabase. We usually initiated NPPV in severe
symptomatic COPD in case of persistent hypercap-
nia after exhaustion of medical treatment (all
patients had received b-agonists, anticholinergic
agents, theophylline, inhaled steroids and on
occasion systemic steroids). In order to examine
the effects of NPPV on stable COPD, we selected
the patients based on the following clinical and
physiological criteria: severe form of the disease according to the
Global Initiative for Chronic Obstructive Lung
Disease (GOLD) IV; FEVo50% of predicted and PaCO2445mmHg
while breathing room air; no clinical signs of exacerbation based on the
definition of Anthonisen et al.29 taken from the
anamnesis; leucocytes o10,000/ul at time of admission;
 CRPp5mg/dl at time of admission;
 pH value X7.35;
 current oxygen therapy (LTOT);
 no previous exposure to domiciliary NPPV;
 exclusion of patients which were switched from
tracheostomy to non-invasive mask ventilation;
 exclusion of patients in which a sleep apnoea was
detected (assessed by polysomnography) and/or
BMI X40 kg/m2.Measurements
Diurnal and nocturnal blood gas measurements
(Rapidlab; Bayer Inc; East Walpole, MA, USA) were
routinely taken from the hyperaemic earlobe,
where the values being closest to the initiation
time of NPPV and showing best oxygenation
(SaO2490% or PaO2460mmHg) were considered
as baseline values. We registered blood gas para-
meters in the daytime during spontaneous breath-
ing of room air and during long-term oxygen
therapy (LTOT) using their usual oxygen flow. Whole
bodyplethysmography (Masterlab; Jaeger Inc;
Wu¨rzburg, Germany) was performed following the
guidelines of the American Thoracic Society,30
based on the reference values of the European
Community for Steel and Coal.31 Inspiratory capa-
city was calculated as the difference between total
lung capacity and intrathoracic gas volume. In-
spiratory mouth occlusion pressure at 100ms (P0.1)
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were measured as previously described.32Control evaluation
Standard practice in our hospital is that all patients
are reviewed after 6 and 12 months for a control
evaluation. We routinely ask about adverse effects
or problems such as leakage, dry mucosal, etc. by
questionnaire. Furthermore, each patient is re-
quired to estimate his daily application time and
quantify the therapy effect on physical capacity
and symptom relief. Simultaneously, the patient’s
statement is compared to the time counter on the
ventilator. Capillary blood gas parameters are
measured twice at night during ventilation and in
the daytime during spontaneous breathing 4–6 h
after nocturnal NPPV under LTOT (usual oxygen
flow). Ventilation parameters are adjusted to
optimize blood gas parameters and nocturnal
oxygen saturation. In addition, bodyplethysmogra-
phy and inspiratory muscle function is performed as
mentioned above.NPPV technique
Before initiation of NPPV a standard commercial
nasal or full facemask of different sizes and types
(nasal mask Gold or Special; Respironics Inc;
Murrysville, PA, USA and NV ultra mirage nasal or
fullface mask; ResMed Inc; North Ryde, Australia)
or, if necessary, an individually manufactured mask
is fitted. Initially, the ventilator is set in the
spontaneous-timed (assist-controlled) mode with
low inspiratory pressure and back-up respiratory
frequency. After a phase of adaptation we gradually
increase the ventilation parameters to the pa-
tient’s comfort level, targeting a tidal volume of
7–10ml/kg. Oxygen is supplemented as required to
achieve an oxygen saturation of more than 90%.
The beneficial effect of the ventilation and oxygen
supplementation is proven during several nights of
repeated measurements of blood gas parameters at
1:00 and 4:00 a.m. from the hyperaemic earlobe. In
case of a persistent hypercapnia, we increase
inspiratory pressure in order to achieve more
effective ventilation. In the patient sample ana-
lyzed there were four different home respirators in
use, although most of our patients were ventilated
with the Onyx plus (Nellcor Puritan Bennett Inc;
Courtaboef Cedex, France) and BIPAP synchrony ST
(Respironics Inc; Murrysville, PA, USA), which work
in a pressure-cycled mode with a highly sensitive
trigger. Additionally, a humidification system is
installed if dry mucous membranes develop.Statistical analysis
The data were collected in a data bank (Microsoft
Accesss) and analyzed with SPSS software (Statis-
tical Package for Social Science; Chicago, IL, USA).
Baseline values for survivors and non-survivors and
patient characteristics for responding to NPPV were
compared using an unpaired t-test. For changes in
functional parameters a two-related-samples test
(Wilcoxon-test) was performed. Results are pre-
sented as percent (%) of change. Relationships
between changes in blood gas parameters, lung
volumes and inspiratory pressure were assessed
using a linear regression model (Pearson-correla-
tion). Results are shown as mean value7standard
deviation (SD). A P-value of o0.05 was considered
to be significant.Results
Patient sample
We registrated 239 patients with COPD in which
NPPV was started. Thirty-seven patients (15.5%)
were excluded because they were switched from
tracheostomy to NPPV and 54 patients (22.6%)
because of detection of a sleep apnoea syndrome.
One hundred and two patients (42.7%) did not fulfil
the other inclusion criteria, mostly due to exacer-
bation (38 patients had clinical signs for exacerba-
tion and 64 patients elevated leucocytes or CRP).
Forty-six patients (19.2%) met the inclusion criteria
mentioned above. Of these patients, four died
within the first 6 months and one patient between 6
and 12 months after initiation of NPPV. Thus, 1-year
survival was 89.1%. One patient had to be
tracheostomized a few weeks after initiation of
NPPV, one patient had been admitted to another
hospital for control evaluations and one patient did
not come to the control investigation at 12 months.
Hence, we could analyze the data of 40 patients at
6 months and 38 patients at 12 months. They were
seen 6.2 (71.7) and 12.7 (72.1) months after
initiation of NPPV.
Patients characteristics at baseline
At initiation of NPPV the median age of all 46
(8 female/38 male) patients fulfilling the inclusion
criteria was 65.2 (76.6) years with a range from
53.1 to 77.9 years. The severity of COPD was
demonstrated by a median PaCO2 of 55.9
(77.3)mmHg in the daytime during spontaneous
breathing of oxygen (0.971.0 l) and an FEV1 of 0.76
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Table 1 Characteristics of survivors and non-
survivors at baseline*.
Variable Survivors
(n ¼ 41)
Non-survivors
(n ¼ 5Þ
Age (yr) 65.576.5 63.177.8
BMI (kg/m2) 26.874.8 24.475.3
SRtot (kPa s) 5.5072.7 9.3474.9
TLC (l) 7.1571.5 8.4471.5
IC (l) 1.2370.30 0.9770.48
RV/TLC (%) 73.578.6 78.577.8y
RV/TLC pred. (%) 185.0721.2 204.676.1y
FEV1 (l) 0.7770.20 0.6570.27
FEV1/FVC (%) 45.3712.9 42.8712.8
P0.1 (kPa) 0.5070.19 0.3670.09
PImax pred. (%) 37.4715.2 36.1712.3
PH 7.4070.03 7.4170.03
PaCO2 (mmHg) 55.977.2 55.879.0
PaO2 (mmHg) 55.0712.2 58.4710.9
BE (mmol/l) 7.973.9 9.673.6
Hb (g/dl) 15.272.1 13.272.2
*Data are presented as mean7SD unless otherwise
indicated.
yPo0.001.
Reduction of hyperinflation in stable COPD 979(70.21) l or 29.0 (78.2) % of predicted. Table 1
shows the data of survivors and non-survivors.
Although we were aware that the size of the groups
was different, it is important to note that non-
survivors seem to have a more severe form of the
disease and were significantly more hyperinflated
(RV/TLC 73.578.6 vs. 78.577.8% or 185.0721.2
vs. 204.676.1% of pred.; Po0:001).0
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Figure 1 Changes in blood gas tensions and base excess
(BE) 6 and 12 months after NPPV. ySignificant difference
in comparison to baseline values (Po0:001).NPPV parameters and ventilator compliance
NPPV was delivered in 42 patients through a nasal
mask, in two patients through a full facemask and
in two patients through an individually manufac-
tured mask. After discharge from the hospital, the
patients were ventilated with an expiratory posi-
tive airway pressure (EPAP) of 3.8 (71.8) cm H20,
an inspiratory positive airway pressure (IPAP) of
19.9 (74.1) cm H2O and a mean respiratory
frequency of 21.3 (73.5)/min. There were no
significant changes in ventilation parameters after
6 and 12 months.
The median daily application time of NPPV,
calculated via the time counter of the ventilator
was 6.1 (71.8) h from discharge to six months and
6.5 (72.8) h from 6 to 12 months. Only two
patients (5%) had ventilator use less than 3 h.Long-term effects of NPPV
Blood gas parameters
Figure 1 shows the changes in blood gas parameters
during the daytime after nocturnal NPPV treatment.
We found a decrease in PaCO2 of 9.379.9mmHg
(15.3716.4%; Po0:001) at 6 and 11.079.3mmHg
(18.4713.5%; Po0:001) at 12 months. Furthermore,
PaO2 (15.6730.5%; Po0:05 resp. 17.8731.3%;
Po0:01) and pH (0.370.5%; Po0:01 resp.
0.470.6% Po0:001) increased at 6 and 12 months
while positive base excess (BE) decreased
(22.0772.4%; Po0:001 resp. 27.3762.8%;
Po0:001). In patients in which nocturnal blood gas
parameter were available at baseline and control
investigation at 1:00 a.m. and 4:00 a.m. as well, we
saw a decrease in PaCO2 at 6 months (n ¼ 30) from
58.378.2 to 47.678.3mmHg (14.2720.7%;
Po0:001) resp. from 60.778.1 to 48.478.2mmHg
(15.9720.0%, Po0:001). At 12 months (n ¼ 28)
similar reductions in PaCO2 to 46.177.7mmHg
(18.0719.5%; Po0:001) at 1:00 a.m. and to
47.477.5mmHg (16.9719.2%; Po0:001) at 4:00
a.m. could be observed.
In comparison, patients with exacerbation
(n ¼ 102) in which blood gas parameters were
available before initiation of NPPV and at 6 and
12 months as well (n ¼ 40), changes in PaCO2, PaO2
and BE were even more pronounced (Table 2).
Lung and inspiratory muscle function after NPPV
We found a significant decrease in RV/TLC at 6
(3.976.4%; Po0:01) and 12 months (5.279.8%;
Po0:001). The median decrease of RV/TLC of
predicted was 15.2729.7% (Po0:01) at 6 and
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Table 2 Changes in blood gases and lung function in stable and exacerbated COPD.
Variable (% of changes) Stable Exacerbated
6 months 12 months 6 months 12 months
PaCO2 15.3716.4y 18.4713.5y 23.6715.7y 24.4717.6y
PaO2 15.6730.5
z 17.8731.3y 17.2738.4y 14.3739.6y
BE 22.0772.4y 27.3762.8y 66.5741.9y 50.6744.3y
RV/TLC 3.976.4y 5.279.8y 9.379.8y 6.479.9y
RV/TLC pred. 15.2729.7y 12.9718.9y 19.3720.6y 14.5719.6y
IC 17.0738.0z 17.1742.6z 26.8752.6z 25.8747.6z
Significant difference (% of changes) in comparison to baseline values.
yPo0:001; yPo0:01; zPo0:05:
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† †
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Figure 2 Changes in RV/TLC and IC 6 and 12 months after NPPV. Significant difference in comparison to baseline values
(yPo0:01; zPo0:05). RV/TLC ¼ residual volume/total lung capacity. IC ¼ inspiratory capacity.
S. Budweiser et al.98012.9718.9% (Po0:001) at 12 months. Simulta-
neously, we observed an increase in inspiratory
capacity at six (17.0738.0%; Po0:05) and 12
months (17.1742.6%; Po0:05) (Fig. 2). Moreover,
there was also a significant increase in FEV1
(19.7733.1% resp. 18.2731.0%; Po0:01) and VC
(18.1734.1% resp. 21.0732.2%; Po0:01) at 6 and
12 months. Again, in patients with exacerbation
(n ¼ 102) in which lung function was performed
before initiation of NPPV and at 6 (n ¼ 35) and 12
months (n ¼ 38), changes in RV/TLC and IC were
more pronounced (Table 2).
In stable COPD, improvements in FEV1 and VC
were significantly correlated to the reduction in
RV/TLC (r ¼ 0:60; Po0:001 resp. r ¼ 0:77;
Po0:001) (Fig. 3). No changes could be detected
in TLC, SRtot and FEV1/VC at these investigation
points. We also found no significant improvement in
the maximal inspiratory muscle force (PImax), nor in
P0.1 or the quotient P0.1/PImax.
Inspiratory pressure levels and response to NPPV
No significant correlation was found between
changes in PaCO2 and IPAP for all patients
(P ¼ 0:08). However, for patients with the mostsevere hyperinflation (RV/TLC475%; n ¼ 18),
changes in PaCO2 and RV/TLC were positively
correlated to inspiratory pressure (r ¼ 0:56 resp.
0.50; Po0:05).Discussion
The main finding of the current study is that, in
stable COPD, the long-term application of noctur-
nal NPPV can decrease hyperinflation in terms of a
reduction in RV/TLC, thereby improving inspiratory
capacity. This reduction in hyperinflation is accom-
panied by a significant and sustained amelioration
of daytime blood gas tensions, specifically a
decrease in PaCO2.
Effects and response to NPPV in comparison
to previous investigations
The long-term effects of NPPV in stable COPD are
still discussed controversially.10,23,24 However, in a
number of studies,11,12,14–18 NPPV has been
shown to reduce daytime PaCO2, which has been
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Figure 3 Correlations between changes in RV/TLC (M12–M0) and FEV1 (M12–M0, r ¼ 0:60; Po0:001) and VC (M12–M0,
r ¼ 0:77; Po0:001) after 12 months NPPV. M, month; RV/TLC, residual volume/total lung capacity; FEV1, forced
expiratory volume in one second; VC, vital capacity.
Reduction of hyperinflation in stable COPD 981frequently explained by sensitization of central
respiratory center.33,34 Nevertheless, the ability of
NPPV to reduce hyperinflation was recognized more
than a decade ago,35 but has not yet been
investigated in a larger collective on a long-term
basis. We detected a significant decrease in RV/
TLC, on average 15.2% pred. at 6 months and 12.3%
pred. at 12 months without changes in TLC,
compared to baseline values. Since we found a
highly positive correlation between changes in RV/
TLC and FEV1 and VC, we presume that deflation
also plays a role in the improvement of these
parameters. Previous long-term investigations of-
ten observed no change in most of the lung function
parameters measured by bodyplethysmography or
spirometry.12,16,17,19–22 However, Perrin et al.36
prospectively evaluated 14 patients on domiciliary
NPPV plus LTOT and found an improvement in VC
and FEV1, but without statistical significance in
their small sample of patients.
In most previous investigations, positive effects
resulting from NPPV possibly were not observed for
several reasons. First, in comparison to patients
with neuromuscular or thoracic restrictive dis-
eases, unsatisfactory ventilator compliance is often
reported for patients with stable COPD, particu-
larly in studies with poor response to NPPV.19,21 In
an outpatient setting, Strumpf et al.19 even
reported an intolerance rate of 63%. In contrast,
we observed a high level of acceptance of NPPV,
which was demonstrated by the daily duration of
ventilator use. Moreover, all but one patient came
to the control investigation and only one patient
had to be tracheotomized. We presume, that the
high compliance rate in our patients could be due
to close supervision and adequate initial adaptation
to NPPV. However, we should also mention, that
patients refusing NPPV within the first several daysand thus discharged without NPPV were not
registered in this analysis.
Furthermore, the effectiveness of nocturnal
ventilation in our study was confirmed by significant
reductions in PaCO2, both in the daytime and at
night, similar to the favourable results reported by
Meecham-Jones et al.18 and Elliot et al.35 Finally, in
three controlled investigations on NPPV in chronic
COPD,19,21,22 the patients were not in a severe
hypercapnic status (46, 50.5 and 50.7mmHg,
respectively) as they were in our sample of
patients.Possible mechanisms underlying the
reduction of hyperinflation
Lung hyperinflation is a major problem in COPD
patients which correlates inversely with functional
status and exercise tolerance.37–40 It is thought that
hyperinflation is the result of
’ ’
air trapping’’ caused
by expiratory airway collapse and augmented
respiratory frequency, leading to intrinsic positive
end expiratory pressure (PEEPi). Supplementary
oxygen has been found to reduce dynamic hyperin-
flation in patients with expiratory flow limitation at
rest and during or after exercise as well.41–43 These
effects had been essentially explained by changes
in ventilatory pattern. Since NPPV therapy also
results in improved blood gas parameters, similar
effects on respiratory pattern could play an
important role in NPPV. Indeed, in stable COPD
patients, a decreased respiratory frequency and
augmented tidal volume during NPPV has already
been observed.44–47 These effects could be pre-
served for spontaneous breathing at least for
responders, as indicated in some clinical stu-
dies.28,44,46 In a controlled prospective trial, Diaz
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deep and slow pattern of breathing, but also a
significant correlation between increase in tidal
volume and a decrease in residual volume and PEEPi
as well. These improvements in breathing patterns
and blood gas parameters during NPPV were more
pronounced at higher pressure support levels.28,45
The importance of high inspiratory pressure was
also demonstrated in our study by a significant
correlation between IPAP and changes in PaCO2 and
RV/TLC, at least for patients with the most severe
hyperinflation.
Another possible explanation for the beneficial
effects on hyperinflation may be that NPPV reduces
the frequency or severity of exacerbations and
thereby reduces any increase in hyperinflation over
time. Although the underlying reasons remain
unclear, some authors have, however, described a
reduction in hospitalization admissions.12,17
As previously discussed,28 effects of NPPV could
also be mediated by reducing airway wall oedema,
thus reducing airway narrowing and decreasing
airway resistance. This could be also beneficial for
mucous clearance.48 As a personal observation,
indeed some patients report substantial secrete
production during nocturnal NPPV.
In our analysis we could not detect any effects of
NPPV on P0.1, PImax or on the ratio of P0.1/PImax,
despite significant changes in lung volumes and
hyperinflation. This somewhat surprising result
could be explained by studies, which indicate that
P0.1 often is not a valid marker for inspiratory drive
in COPD.49Limitations of study
The major limitation of this long-term study is that
it is retrospective and uncontrolled. To ascertain
clinical stability, we based our selection criteria on
recently published prospective stu-
dies.16,17,22,28,46,47 However, a clear definition of
exacerbation does not exist50 and apparently
clinically stable COPD patients also have increased
circulating levels of cytokine mediators.51,52 The
clinical criteria for exacerbation proposed by
Anthonisen et al.29 seemed to be verifiable in this
study since data could be taken from the ana-
mnesis. Additionally, laboratory parameters were
used to exclude patients with current severe
systemic inflammation. Indeed, since changes in
blood gases and lung function were, as suspected,
more pronounced in patients with exacerbation,
the inclusion criteria presumably were appropriate.
In the absence of a control group we cannot
completely discount the bias that the reportedimprovement in hyperinflation could be due to
medical treatment. In recent years some clinical
trials have demonstrated that long-acting b-ago-
nists as well as parasympatholytic agents are able
to reduce hyperinflation.53–55 However, medical
therapy had been already maximized at baseline
and thus should not be responsible for
the described effects as has also been confirmed
in the controlled, but short-term trial by Diaz
et al.28
In summary, we analyzed a well-selected patient
group with stable COPD, showing high compliance
and demonstrating effective nocturnal ventilation.
Thus, we conclude that the current study supports
the long-term use of NPPV as an effective modality,
particularly for severe hypercapnic patients. We
could demonstrate that the improvement in blood
gas parameters is accompanied by a reduction in
hyperinflation and an increase in inspiratory capa-
city. Deflation, due to an improved respiratory
pattern may play a central role in the beneficial
effects of NPPV in stable COPD, but this has yet to
be proven in a prospective long-term controlled
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